Pranit Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pranit Singh has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aditi Saha
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA
13 shared publications - Aleksandr Lazaryan
Moffitt Cancer Center, Tampa, Florida, United States
13 shared publications - Asmita Mishra
Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
13 shared publications - Bijal D. Shah
Moffitt Cancer Center, Tampa, USA
13 shared publications - Christina A. Bachmeier
Moffitt Cancer Center, Tampa, Florida
13 shared publications - Ciara Louise Freeman
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
13 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6: Association of corticosteroids and SMI loss.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6: Association of corticosteroids and SMI loss.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S7: Comparison of Cytokine expansion in Sarcopenic vs. Non-sarcopenic Individuals and Association with SMI Loss.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S7: Comparison of Cytokine expansion in Sarcopenic vs. Non-sarcopenic Individuals and Association with SMI Loss.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 4: PFS and OS Stratified by Sarcopenia and SMI Loss Status at Day 30 and Day 90.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 4: PFS and OS Stratified by Sarcopenia and SMI Loss Status at Day 30 and Day 90.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S3: Longitudinal Changes in Skeletal Muscle Index (SMI) Stratified by Gender and Sarcopenia Status Pre- and Post-CAR T-cell Therapy.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S3: Longitudinal Changes in Skeletal Muscle Index (SMI) Stratified by Gender and Sarcopenia Status Pre- and Post-CAR T-cell Therapy.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S4: Mixed model coefficient estimates for SMI and total adipose tissue with sarcopenia status and time points.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S4: Mixed model coefficient estimates for SMI and total adipose tissue with sarcopenia status and time points.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S1: Survival Analysis by Baseline BMI Category.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S1: Survival Analysis by Baseline BMI Category.